The role of high-density lipoproteins in diabetes and its vascular complications

Nathan K.P. Wong, Stephen J. Nicholls, Joanne T.M. Tan, Christina A. Bursill

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Almost 600 million people are predicted to have diabetes mellitus (DM) by 2035. Diabetic patients suffer from increased rates of microvascular and macrovascular complications, associated with dyslipidaemia, impaired angiogenic responses to ischaemia, accelerated atherosclerosis, and inflammation. Despite recent treatment advances, many diabetic patients remain refractory to current approaches, highlighting the need for alternative agents. There is emerging evidence that high-density lipoproteins (HDL) are able to rescue diabetes-related vascular complications through diverse mechanisms. Such protective functions of HDL, however, can be rendered dysfunctional within the pathological milieu of DM, triggering the development of vascular complications. HDL-modifying therapies remain controversial as many have had limited benefits on cardiovascular risk, although more recent trials are showing promise. This review will discuss the latest data from epidemiological, clinical, and pre-clinical studies demonstrating various roles for HDL in diabetes and its vascular complications that have the potential to facilitate its successful translation.

LanguageEnglish
Article number1680
JournalInternational Journal of Molecular Sciences
Volume19
Issue number6
DOIs
Publication statusPublished - 1 Jun 2018

Keywords

  • Apolipoprotein A-I
  • Atherosclerosis
  • Complications
  • Diabetes mellitus
  • Dysfunctional
  • Dyslipidaemia
  • High-density lipoprotein
  • Macrovascular
  • Microvascular

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

@article{0772bb0804264f2c9df5390d2608d289,
title = "The role of high-density lipoproteins in diabetes and its vascular complications",
abstract = "Almost 600 million people are predicted to have diabetes mellitus (DM) by 2035. Diabetic patients suffer from increased rates of microvascular and macrovascular complications, associated with dyslipidaemia, impaired angiogenic responses to ischaemia, accelerated atherosclerosis, and inflammation. Despite recent treatment advances, many diabetic patients remain refractory to current approaches, highlighting the need for alternative agents. There is emerging evidence that high-density lipoproteins (HDL) are able to rescue diabetes-related vascular complications through diverse mechanisms. Such protective functions of HDL, however, can be rendered dysfunctional within the pathological milieu of DM, triggering the development of vascular complications. HDL-modifying therapies remain controversial as many have had limited benefits on cardiovascular risk, although more recent trials are showing promise. This review will discuss the latest data from epidemiological, clinical, and pre-clinical studies demonstrating various roles for HDL in diabetes and its vascular complications that have the potential to facilitate its successful translation.",
keywords = "Apolipoprotein A-I, Atherosclerosis, Complications, Diabetes mellitus, Dysfunctional, Dyslipidaemia, High-density lipoprotein, Macrovascular, Microvascular",
author = "Wong, {Nathan K.P.} and Nicholls, {Stephen J.} and Tan, {Joanne T.M.} and Bursill, {Christina A.}",
year = "2018",
month = "6",
day = "1",
doi = "10.3390/ijms19061680",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

The role of high-density lipoproteins in diabetes and its vascular complications. / Wong, Nathan K.P.; Nicholls, Stephen J.; Tan, Joanne T.M.; Bursill, Christina A.

In: International Journal of Molecular Sciences, Vol. 19, No. 6, 1680, 01.06.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The role of high-density lipoproteins in diabetes and its vascular complications

AU - Wong, Nathan K.P.

AU - Nicholls, Stephen J.

AU - Tan, Joanne T.M.

AU - Bursill, Christina A.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Almost 600 million people are predicted to have diabetes mellitus (DM) by 2035. Diabetic patients suffer from increased rates of microvascular and macrovascular complications, associated with dyslipidaemia, impaired angiogenic responses to ischaemia, accelerated atherosclerosis, and inflammation. Despite recent treatment advances, many diabetic patients remain refractory to current approaches, highlighting the need for alternative agents. There is emerging evidence that high-density lipoproteins (HDL) are able to rescue diabetes-related vascular complications through diverse mechanisms. Such protective functions of HDL, however, can be rendered dysfunctional within the pathological milieu of DM, triggering the development of vascular complications. HDL-modifying therapies remain controversial as many have had limited benefits on cardiovascular risk, although more recent trials are showing promise. This review will discuss the latest data from epidemiological, clinical, and pre-clinical studies demonstrating various roles for HDL in diabetes and its vascular complications that have the potential to facilitate its successful translation.

AB - Almost 600 million people are predicted to have diabetes mellitus (DM) by 2035. Diabetic patients suffer from increased rates of microvascular and macrovascular complications, associated with dyslipidaemia, impaired angiogenic responses to ischaemia, accelerated atherosclerosis, and inflammation. Despite recent treatment advances, many diabetic patients remain refractory to current approaches, highlighting the need for alternative agents. There is emerging evidence that high-density lipoproteins (HDL) are able to rescue diabetes-related vascular complications through diverse mechanisms. Such protective functions of HDL, however, can be rendered dysfunctional within the pathological milieu of DM, triggering the development of vascular complications. HDL-modifying therapies remain controversial as many have had limited benefits on cardiovascular risk, although more recent trials are showing promise. This review will discuss the latest data from epidemiological, clinical, and pre-clinical studies demonstrating various roles for HDL in diabetes and its vascular complications that have the potential to facilitate its successful translation.

KW - Apolipoprotein A-I

KW - Atherosclerosis

KW - Complications

KW - Diabetes mellitus

KW - Dysfunctional

KW - Dyslipidaemia

KW - High-density lipoprotein

KW - Macrovascular

KW - Microvascular

UR - http://www.scopus.com/inward/record.url?scp=85048280957&partnerID=8YFLogxK

U2 - 10.3390/ijms19061680

DO - 10.3390/ijms19061680

M3 - Review article

VL - 19

JO - International Journal of Molecular Sciences

T2 - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 6

M1 - 1680

ER -